Details of the Drug

General Information of Drug (ID: DM98OEQ)

Drug Name
5-hydroxy-1H-indole-3-acetic acid
Synonyms
5-Hydroxyindole-3-acetic acid; 54-16-0; 5-HIAA; 2-(5-hydroxy-1H-indol-3-yl)acetic acid; 5-Hydroxyindoleacetic acid; 5-Hydroxyheteroauxin; (5-Hydroxy-1H-indol-3-yl)acetic acid; 5-Oxyindoleacetic acid; 5-Hydroxy-IAA; 5-Hydroxyindolacetic acid; 5-Hydroxy-3-indoleacetic acid; 5-Hydroxyindol-3-ylacetic acid; Hydroxyindoleacetic acid; 5-Hydroxy-1H-indole-3-acetic acid; 5-Hydroxyindolylacetic acid; 1H-Indole-3-acetic acid, 5-hydroxy-; 1321-73-9; Indole-3-acetic acid, 5-hydroxy-; 5-Hydroxyindoleacetate; UNII-YHC763JY1P; NSC 90432
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 191.18
Topological Polar Surface Area (xlogp) 1.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C10H9NO3
IUPAC Name
2-(5-hydroxy-1H-indol-3-yl)acetic acid
Canonical SMILES
C1=CC2=C(C=C1O)C(=CN2)CC(=O)O
InChI
InChI=1S/C10H9NO3/c12-7-1-2-9-8(4-7)6(5-11-9)3-10(13)14/h1-2,4-5,11-12H,3H2,(H,13,14)
InChIKey
DUUGKQCEGZLZNO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1826
ChEBI ID
CHEBI:27823
CAS Number
54-16-0
TTD ID
D02VPC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Binder [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
DNA topoisomerase I (TOP1) DTT TOP1 6.65E-01 0.2 0.39
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
4 Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
7 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
8 Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
9 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
10 Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.